Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to fund medicines ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s decision to fund medicines for a further five health conditions, including ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

Personalized Cancer Treatment Using 3D Bioprinting Technology ... Could the Contraceptive Pill Reduce Risk of Ovarian Cancer? Feb. 3, 2025 — It's a little pill with big responsibilities.

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...

total of 218 consecutive patients with pathologically confirmed neuroendocrine ... resection after chemotherapy is still alive after 15.2 months without evidence of tumor recurrence.